Results
Your Query
| Subject | Predicate | Object |
|---|---|---|
| http://purl.uniprot.org/unirules/MF_04083#construct-template-211 | http://spinrdf.org/sp#subject | http://purl.uniprot.org/unirules/MF_04083#construct-var-25 |
| http://purl.uniprot.org/unirules/MF_04083#construct-template-211 | http://spinrdf.org/sp#predicate | http://www.w3.org/2000/01/rdf-schema#comment |
| http://purl.uniprot.org/unirules/MF_04083#construct-template-211 | http://spinrdf.org/sp#object | "Inhibitors targeting HIV-1 viral envelope proteins are used as antiretroviral drugs. Attachment of virions to the cell surface via non-specific interactions and CD4 binding can be blocked by inhibitors that include cyanovirin-N, cyclotriazadisulfonamide analogs, PRO 2000, TNX 355 and PRO 542. In addition, BMS 806 can block CD4-induced conformational changes. Env interactions with the coreceptor molecules can be targeted by CCR5 antagonists including SCH-D, maraviroc (UK 427857) and aplaviroc (GW 873140), and the CXCR4 antagonist AMD 070. Fusion of viral and cellular membranes can be inhibited by peptides such as enfuvirtide and tifuvirtide (T 1249). Resistance to inhibitors associated with mutations in Env are observed. Most of the time, single mutations confer only a modest reduction in drug susceptibility. Combination of several mutations is usually required to develop a high-level drug resistance."xsd:string |
| http://purl.uniprot.org/unirules/MF_04083#construct | https://hamap.expasy.org/rdf/vocab#addsTriple | http://purl.uniprot.org/unirules/MF_04083#construct-template-211 |
| http://purl.uniprot.org/unirules/MF_04083#construct-template-list-211 | http://www.w3.org/1999/02/22-rdf-syntax-ns#first | http://purl.uniprot.org/unirules/MF_04083#construct-template-211 |